FDA approved pharmacotherapy options for alcohol use disorders remain limited, with only three currently approved compounds (disulfiram, naltrexone and acamprosate). Recent studies highlight the potential for medications used for the treatment of other indications to be examined for the treatment of alcohol use disorders. Study of additional agents, particularly those that act through novel mechanisms, is needed to expand the range of pharmacotherapy options for alcohol use problems. Extensive preclinical studies indicate that neuroactive steroids medicate important effects of alcohol and support the examination of neuroactive steroid modulators as treatment options for alcohol use problems. Dutasteride, a widely prescribed medication for benign prostatic hypertrophy, bloci

Public Health Relevance

Heavy drinking remains a significant public health problem. Although several medications have been shown to help patients stop or reduce drinking, additional medication options are needed as there is considerable variablitity in effectiveness or tolerability of existing medications for individual patients. This study will examine a medication approved for other conditions for its potential use to help men reduce or stop drinking.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Comprehensive Center (P60)
Project #
2P60AA003510-36
Application #
8401273
Study Section
Special Emphasis Panel (ZAA1-GG (50))
Project Start
Project End
Budget Start
2012-12-25
Budget End
2013-11-30
Support Year
36
Fiscal Year
2013
Total Cost
$287,892
Indirect Cost
$117,758
Name
University of Connecticut
Department
Type
DUNS #
022254226
City
Farmington
State
CT
Country
United States
Zip Code
06030
Petry, Nancy M; Alessi, Sheila M; Byrne, Shannon et al. (2015) Reinforcing adherence to antihypertensive medications. J Clin Hypertens (Greenwich) 17:33-8
O'Hara, Ross E; Armeli, Stephen; Tennen, Howard (2015) College students' drinking motives and social-contextual factors: Comparing associations across levels of analysis. Psychol Addict Behav 29:420-9
Petry, Nancy M; Alessi, Sheila M; Barry, Danielle et al. (2015) Standard magnitude prize reinforcers can be as efficacious as larger magnitude reinforcers in cocaine-dependent methadone patients. J Consult Clin Psychol 83:464-72
O'Hara, Ross E; Armeli, Stephen; Tennen, Howard (2014) College students' daily-level reasons for not drinking. Drug Alcohol Rev 33:412-9
O'Hara, Ross E; Armeli, Stephen; Tennen, Howard (2014) Drinking-to-cope motivation and negative mood-drinking contingencies in a daily diary study of college students. J Stud Alcohol Drugs 75:606-14
Andrade, Leonardo F; Barry, Danielle; Litt, Mark D et al. (2014) Maintaining high activity levels in sedentary adults with a reinforcement-thinning schedule. J Appl Behav Anal 47:523-36
Arias, Albert J; Covault, Jonathan; Feinn, Richard et al. (2014) A GABRA2 variant is associated with increased stimulation and 'high' following alcohol administration. Alcohol Alcohol 49:1-9
Weiss, Lindsay M; Petry, Nancy M (2014) Substance abuse treatment patients with early onset cocaine use respond as well to contingency management interventions as those with later onset cocaine use. J Subst Abuse Treat 47:146-50
Milivojevic, Verica; Feinn, Richard; Kranzler, Henry R et al. (2014) Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3?-HSD type 2 (17?-HSD type 5), moderates the subjective effects of alcohol. Psychopharmacology (Berl) 231:3597-608
Kranzler, Henry R; Armeli, Stephen; Feinn, Richard et al. (2014) GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink. Int J Neuropsychopharmacol 17:1549-56

Showing the most recent 10 out of 87 publications